Advertisement

Topics

Companies Related to "Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study" [Most Relevant Company Matches] - Page: 4 RSS

22:19 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study" found in our extensive corporate database of over 50,000 company records.

Showing "Antigonadotropin Leuprolide Alzheimer Disease Drug INvestigation ALADDIN Study" Companies 76–100 of 6,100+

Relevant

Laxdale Limited

Psychiatric and CNS diseases, including schizophrenia, bipolar disorders, depression and alzheimer's disease.


Pharnext SAS

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charco...

Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec(®) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute ...


Panacea Pharmaceuticals

Panacea Pharmaceuticals, Inc. focuses on developing and utilizing protein-based technologies to detect and identify changes associated with and involved in diseases of the central nervous system such as Alzheimer's disease, brain tumors, transmissible spongiform encephalopathies, and Lewy Body diseases such as Parkinson's disease. Changes in disease-relevant proteins by altered expression, post-tr...

Applied NeuroSolutions, Inc.

Applied NeuroSolutions, Inc. (OTC BB:APSN - News) is developing diagnostics and therapeutics to detect and treat Alzheimer's disease (AD) building on discoveries originating from the Albert Einstein College of Medicine. Applied NeuroSolutions is in a collaboration with Eli Lilly and Company to develop novel therapeutic compounds to treat the progres...

BioClin Therapeutics, Inc.

BioClin Therapeutics, Inc. is a privately-held clinical stage drug development company developing biologics to address medical conditions in areas of high unmet need. The company’s lead candidate is B-701, a potential first-in-class human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor 3). B-701 is currently being evaluated in t...

Cognoptix

Cognoptix, a privately held medical technology company headquartered in Acton, Mass., is focused on developing and commercializing an in-office, drug/device diagnostic system as an aid in the early detection of Alzheimer’s Disease (AD). Its lead investor is Inventages Venture Capital, one of the world’s largest life sciences-, nutrition- and well...

Alzheimer's Association

The Alzheimer’s Association, the world leader in Alzheimer research and support, is the first and largest voluntary health organization dedicated to finding prevention methods, treatments and an eventual cure for Alzheimer’s

Opsona Therapeutics Limited

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

Tetra Discovery Partners Inc.

Tetra Discovery Partners is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Alzheimer's disease, neuro-developmental conditions such as Fragile X syndrome, traumatic brain injury, and other brain disorders. Tetra uses structure-guided drug design to discover m...

Mind-NRG

Mind-NRG is devoted to the development of NRG-101 in psychiatric and neurologic diseases. NRG-101 is a neurotrophic factor with disease modifying potential that naturally crosses the blood-brain barrier through a receptor-mediated transport to reach its target in the brain. Currently at the pre-clinical stage, NRG-101 is being developed to treat d...

D-Pharm Ltd

D-Pharm (http://www.dpharm.com) is a technology-driven biopharmaceutical company focused on the discovery and development of innovative proprietary drugs for the treatment of central nervous system disorders and cancer. D-Pharm is a leader in design and development of lipid-like medicine and its products are new chemical entities (NCEs) derived from its proprietary platform technology. The dru...

DMI BioSciences, Inc.

DMI BioSciences, Inc. is a privately-held biopharmaceutical company that discovers and develops small molecule and peptide-based pharmaceuticals and biomarkers for acute and chronic inflammation. DMI focuses on immunologic, vascular and CNS diseases, including acute coronary syndrome, multiple sclerosis, Alzheimer's disease, asthma and cancer. DMI is co-developing several of its drug candidates wi...

Neurogenetic Pharmaceuticals, Inc.

Neurogenetic Pharmaceuticals, Inc. (NGP) is a biopharmaceutical discovery and development company founded in 2009 which is focused on developing innovative drug therapies for use in the treatment of neurodegenerative disorders such as Alzheimer’s disease. Based in San Diego, Calif., the company’s next objective is to obtain an Investigational New...

Parkinson?s Unity Walk

Parkinson's disease is the second most common chronic neurological disorder in older adults after Alzheimer's, affecting approximately one percent of people over age 60. Approximately 15 percent of patients develop Parkinson's disease before the age of 50. Every nine minutes someone is diagnosed with Parkinson's disease. Symptoms include tremor, muscle rigidity, slowed motion, shuffling gait, and ...

Medical Care Corporation

Medical Care Corporation specializes in the development of medical technologies that help healthcare professionals deliver "best-practice" levels of care in the field of dementia. Our online patient assessment products enable early detection of memory loss due to Alzheimer's disease allowing for timely intervention when treatment is most effective. The primary problem in treating Alzheimer's disea...

Neurimmune Therapeutics AG

Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases. The current pipeline comprises programs in neurodegeneration including Alzheimer's and Parkinson's diseases, Tauopathies and Amyotrophic Lateral Sclerosis or Lou Gehrig's Disease. Based on its un...

Allon Therapeutics Inc

Allon Therapeutics Inc. (TSX:NPC) is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer’s disease, mild cognitive impairment, traumatic brain injury, stroke, multiple sclerosis and neuropathy. Allon’s drug discovery platform has resulted in the development of a unique class of peptide compounds that has demonstrated broad effic...

Avraham Pharmaceuticals Ltd.

Founded in 2010, Avraham Pharmaceuticals has raised more than $12 million to advance the development of its unique, multi-functional drug substance, ladostigil, currently undergoing two Phase 2 clinical trials for the treatment of Alzheimer's disease and mild cognitive impairment. The Company has been capitalized by Clal Biotechnology Industries Ltd., the ...

Neurochem

Neurochem Inc. is a dynamic, highly energized biopharmaceutical company with an exciting vision and future, located in the Parc scientifique et de haute technologie de Laval, in Quebec, Canada.Neurochem's strategic plan focuses on the further development of a strong, steadily expanding pipeline of product candidates addressing vital unmet medical needs. These products focus primarily on neurologic...

Elan

Elan Corporation, plc is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain. Elan's focus on improving the health of patients suffering from chronic and debilitating conditions is exemplified by its breakthrough research program in Alzheimer's disease, where it has...

The North American Society for the Study of Celiac Disease

Ribi ImmunoChem Research Incorporated

Ribi ImmunoChem Research Inc., is engaged in the development of biopharmaceutical products that stimulate theimmune system to generate a cascade of natural agents and signals to prevent and treat human disease. Ribi immunostimulants can be combined with disease-specific antigens which may direct the immune system to respond to a particular cancer or infectious disease or can be used to modulate th...

Intra-Cellular Therapies, Inc. (ITI)

Intra-Cellular Therapies, Inc. (ITI) is a biotechnology company developing novel therapeutics for the treatment of depression, schizophrenia, Alzheimer's and Parkinson's disease and other disorders of the Central Nervous System. Using IntraPath, its broad technology platform, ITI has identified nerve-signaling proteins, validated their roles in vivo and is currently using these proteins as targets...

M3 Biotechnology, Inc.

M3 Biotechnology is a clinical stage company with a novel platform of disease-modifying regenerative therapies particularly relevant to neurodegenerative diseases, with a focus on Alzheimer’s. M3’s lead asset, NDX-1017, modifies growth factor systems and is advanced as a first-in-class, disease-modifying treatment with the potential to restore lo...


More From BioPortfolio on "Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks